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A 41 year-old Caucasian gentleman presented to his general practitioner (GP) for 
a routine blood pressure (BP) check. The patient was asymptomatic and had an 
initial reading of 154/115mmHg. Ambulatory BP monitoring (ABPM) was 
requested, revealing a subsequent reading of 137/89mmHg. 
 
Further assessment was arranged; including an ECG (no R wave progression or 
large P waves), total cholesterol 6.8mmol/L (reference <5mmol/L), and a 
fundoscopy examination revealed no silver wiring or other abnormalities. There 
was no evidence of urinary microalbuminuria.   
 
He consumes a moderate amount of alcohol on weekends only, and smokes 10 
cigarettes a day. He has a medical history of depression and dyspepsia for which 
he takes omeprazole and sertraline daily. He has no family history of 
cardiovascular disease (CVD). 
 
His QRISK2 score was calculated as 10.3%. He was concerned about what this 
meant for his health and wanted help in making decisions about how to proceed. 
  
  
Question 1 - Which guidelines and tools could be used to help facilitate a 
discussion that leads to a shared decision with the patient? 
 
Short Answer 
 
The UK National Institute for Health and Care Excellence (NICE) has developed a 
clinical guideline (CG181, published in 2014) on lipid modification for primary 
and secondary prevention of CVD1. 
 
Patient decision aids (PDA) are valuable tools that present evidence-based 
estimates of the risks and benefits of treatment options to help facilitate shared, 
patient-focused decision making. 
 
Long Answer 
 
The NICE guideline offers evidence-based advice and recommendations on the 
treatment of people currently with, or at risk, of CVD. Other international 
equivalent guidelines from the European Society of Cardiology (ESC) and the 
American College of Cardiology (ACC) also provide robust guidance tailored to 
their respective populations2,3.  
 
Shared decision making (SDM) is an increasingly important concept in 
healthcare4. It refers to a collaborative process whereby health care decisions 
are made jointly by individuals and their clinicians, taking into account the best 
scientific evidence available as well as values and preferences.  PDAs are an 
important means to support this process and seek to give individuals clear 
information about the benefits and risks of proposed interventions and 
treatments5. Unlike the generic background information provided by patient 
information leaflets, they aim to supplement the interaction between healthcare 
professionals and individuals6. A recent Cochrane review concluded that PDAs 
increase patients’ involvement in decisions about their care and improve their 
knowledge; though there is uncertainty about the effectiveness of strategies to 
improve their adoption, given the low quality of evidence7.  
 
NICE have developed a PDA on taking statins alongside their professional 
guidelines on lipid modification in CVD8,9. The ESC and ACC guidelines also place 
an emphasis on shared decision making2,3.  
 
PDAs present relative and absolute risks in context for patients to better 
understand the benefit or harm that an intervention, or lack thereof, may bring. 
They can also provide illustrations that portray information in an accessible 
format.   
 
Randomised controlled trials have shown that these tools promote dialogue and 
increase joint deliberation10. They also pivot the focus of consultations towards 
patients as the data is reviewed11.  The evidence suggests they do not increase 
the uptake of therapy overall and indeed, may do the opposite12. 
 
Patients should be informed about the limitations of CVD risk assessment tools, 
which can only provide an approximate value of risk and may misclassify high 
risk status on an individual level13.  
 
It should be noted that not all patients will value involvement in making 
decisions about their health, nor be able to understand the information that is 
presented to them14. Patients should be offered a choice on what they feel 
comfortable with, as many will simply want clear advice15.  
 
Equally, some patients may take their own initiative with self-assessment tools 
available online. Healthcare professionals should consider counselling patients 
on the use of these tools, as unexpected or contradictory results may be 
misunderstood or disregarded16.
Question 2 - What are the important principles of lifestyle advice to deliver? 
 
Short Answer 
 
The NICE guideline CG181 recommends that following CVD risk assessment, 
lifestyle modification benefits should be discussed with the patient before 
offering any pharmacological treatment for primary prevention. This should 
include diet, physical activity, smoking and alcohol consumption. 
 
Long Answer 
 
Risk Assessment 
When performing risk assessment, the latest NICE guideline recommends using 
the QRISK2 tool to assess CVD risk for primary prevention of CVD in patients up 
to and including 84 years of age1,17. QRISK2 is considered better calibrated for 
UK CVD event rates than other tools. The Framingham risk tool, for example, is 
based on USA prospective cohort studies and is widely used in other countries. 
The NICE guidance advises that patients should not be opportunistically 
assessed; those over the age of 40 should have their CVD risk reviewed on an 
annual basis, with priority for a formal review if their QRISK2 is more than 10%.  
 
The most important principle is to encourage individuals to participate in 
reducing their CVD risk. This involves ascertaining any prior knowledge and 
feelings about their health. Confidence, readiness for change and health beliefs 
must also be explored, as these will attitudes to changing lifestyle18. Decisions 
should be made in partnership with the patient and clinicians should check if the 
management plan has been fully agreed. 
 
Lifestyle Advice 
In general, individuals should be encouraged to optimise their diet and physical 
activity, stop smoking, and moderate their alcohol consumption. Dietary advice 
should focus on a balanced diet and the NHS Choices website offers many 
suggestions on healthy cooking methods19. Although some reports have 
advocated the Mediterranean diet as a preferred choice as it is supported by trial 
evidence, the NICE guidelines did not use the term ‘Mediterranean’ in their 
recommendations, concerned about confusion as to how this term might be 
interpreted, and potential adverse economic effects for those with limited 
budgets. 1,20,21,22.  Nevertheless, many of the components of the ‘Mediterranean 
diet’ are incorporated into the general NICE dietary advice: eating at least 5 
portions of fruit and vegetables a day; preferring wholegrain options for starchy 
foods; reducing sugar intake; having at least 2 portions of fish per week and 4-5 
portions of unsalted nuts, seeds and legumes per week. 
 
Patients at high risk or pre-existing CVD should have a diet where 30% or less of 
energy intake comes from fat, and should avoid saturated fats where possible. 
 
Salt intake should also be monitored, as reducing this can help to ameliorate 
elevated blood pressure23. 
 
Individual circumstances should be taken into consideration and patients should 
be encouraged to have a healthy approach to changing their behaviour in 
relation to food. In line with NICE’s recommendations on obesity, weight 
management is also vital, and patients who are overweight should have 
discussions about maintaining a healthy weight and be supported and guided to 
appropriate services to facilitate this24. 
 
Any advice on physical activity should also take into account the patient’s 
circumstances and preferences, particularly with respect to co-morbidities and 
mobility. NICE recommends that these patients should follow the national 
guidance for physical activity in the general population1. High-risk individuals 
who are capable should aim for at least 150 minutes of moderate exercise per 
week, or 75 minutes of vigorous exercise; or a combination of both25. It is also 
recommended that muscle-strengthening activities in major muscles groups are 
also carried out. 
 
Alcohol should be moderated to 3-4 units/day for men and 2-3/day for women, 
with avoidance of heavy ‘binge’ drinking where possible. It is particularly 
important to address the issue of smoking, as in many cases including this one, 
smoking cessation is likely to be one of the most effective interventions to 
improve the overall CVD risk profile 26. The NHS Stop Smoking Services offer an 
intensive support service for people looking to stop smoking and depending on 
assessment of nicotine dependence, pharmacotherapy and behavioural 
interventions (or a combination of both) may be considered27. 
 
 
 
 
 
  
Question 3 – Is pharmacological therapy indicated in this patient? 
 
Short Answer 
 
The ABPM reading of 137/89 represents uncomplicated stage 1 hypertension 
and drug treatment is not indicated according to current NICE guidance. 
Although the CVD risk is over 10% and NICE guidance suggests statin treatment 
can be considered in this range, an initial period of supported lifestyle 
modification should be offered to the patient at this stage. 
 
Long Answer 
The patient’s initial blood pressure reading was 154/115mmHg with a 
subsequent ABPM reading of 137/89mmHg. According to current NICE guidance 
(CG127), if the diastolic reading continued to be greater than 110mmHg, the 
patient would be classified as having severe hypertension and antihypertensive 
medication would be warranted23. Given the physiological variability of blood 
pressure, ABPM is recommended to give a more accurate diagnosis and in 
particularly, negate the ‘white coat’ effect. This was appropriately organised for 
this patient and the result of 137/89mmHg represents uncomplicated (low risk 
of CVD) stage 1 hypertension25. The ESC and ACC recommend starting 
pharmacological therapy for uncomplicated stage 1 hypertension, whereas NICE 
and the National Heart Foundation of Australia suggest educating patients on 
lifestyle advice rather than initially considering pharmacological options28.  
 
Lifestyle interventions are the overriding priority for this patient and will be the 
mainstay of the current management approach.  If, after a period of lifestyle 
modification, the 10-year CVD risk continues to be above 10% using the QRISK2 
assessment tool, a statin may be offered. Any such decision to start treatment in 
the future should be taken in collaboration with the patient, and the job of the 
doctor would be to help share knowledge about the best available evidence of 
risks and benefits. 
 
The NICE lipid guideline (CG181) suggests that when a decision has jointly been 
made to commence statin therapy for the primary prevention of CVD, 
atorvastatin 20mg once daily should be the routine choice. However, for patients 
with pre-existing cardiovascular disease, a higher dose of 80mg is indicated.  
 
Statins are one of the commonest drugs prescribed in the NHS29. Despite their 
widespread use and tolerability, they have been associated with a variety of 
adverse effects. Myalgia is particularly commonly reported and it is therefore 
important to ask about generalised, unexplained muscle pains before 
commencing treatment1. If present, creatine kinase levels should be checked and 
this is also the test of choice in individuals who develop symptoms whilst taking 
statins1. There is also an elevated risk of developing type 2 diabetes whilst on 
statin therapy, although a meta-analysis of statin trials revealed that treating 
around 255 patients with statins for 4 years results in one extra case of 
diabetes30. Counselling about the possibility of developing these unintended 
affects is therefore an important aspect of discussions about initiation. 
 
In cases where CVD risk is at a level where intervention is warranted but an 
individual chooses not to commence treatment, they should be advised that their 
CVD risk should be reassessed again in the future1. 
 
ESC guidelines recommend the use of the SCORE system to measure CVD risk31. 
Like NICE, they advise using a threshold of 10% to consider initiating 
pharmacological treatment and concur with the recommendations suggesting an 
initial period of lifestyle intervention2. ACC guidelines, meanwhile, suggest the 
use of race and sex-specific pooled cohort equations32. They suggest the 
initiation of statin therapy in primary prevention patients with a predicted 10-
year risk of greater than or equal to 7·5%, and consideration of statin therapy in 
patients with 10-year risks of between 5% and 7·5%33.  
  
Question 4 – When would referral to secondary care be warranted? 
 
Short Answer 
 
Where the total cholesterol is >9.0mmol/L, or non-high density lipoprotein 
(HDL)-cholesterol concentration >7.5mmol/L, a referral to a specialist secondary 
care service is indicated. This also applies if the triglyceride concentration is 
>20mmol/L and not due to poor glycaemic control or excess alcohol1. A 
specialist evaluation for secondary causes of hypertension and potential target 
organ damage can be considered.    
 
Long Answer 
 
The vast majority of CVD risk management can be successfully looked after in 
primary care, however where appropriate, specialist lipid services should be 
utilised where the lipid management can be optimised and CVD risk further 
reduced34. It should be noted that common secondary causes of dyslipidaemia 
should be excluded before a referral is made. These include; uncontrolled 
diabetes, hypothyroidism, liver disease, excess alcohol and nephrotic syndrome1.   
 
Patients should be asked to provide a full lipid profile (a fasting sample is not 
needed); total cholesterol, (HDL)-cholesterol, non-HDL-cholesterol, and 
triglyceride concentrations, before commencing lipid modification therapy. 
Familial hypercholesterolaemia should be suspected if the total cholesterol is 
greater than 7.5 mmol/L and if the patient has a family history of premature 
coronary heart disease1.  
 
A repeat fasting triglyceride concentration is recommended if an initial 
triglyceride count is 10-20mmol/L, within a two week period but after five days. 
One should seek specialist advice if the triglyceride concentration remains above 
10mmol/L.    
 
The NICE guidelines encourage consideration of secondary causes of 
hypertension in those under 40 with stage 1 hypertension and no evidence of 
CVD, target organ damage, renal pathology or diabetes mellitus. A more detailed 
assessment of potential target organ damage should be undertaken as 10-year 
risk assessments in such people can underestimate the lifetime risk of 
cardiovascular events in this cohort23.   
 
 
  
Patient outcome 
 
The GP and patient had a discussion as to what the QRISK2 score means and the 
implications of this on the future health of the patient. The options of reducing 
his risk were explored; namely, lifestyle modifications and the use of statin 
therapy.  
 
After consideration, and an initial attempt at lifestyle measures, the patient 
opted for pharmacological therapy to further reduce his CVD risk through a PDA 
and external reading, and was subsequently commenced on atorvastatin 20mg 
once daily.  
 
He has not suffered side effects of statin therapy and remains to be compliant 
with his medication. He is also aware of the importance of continuing to actively 
make lifestyle changes for improving his hypertension and improving his overall 
cardiovascular risk. 
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